Last reviewed · How we verify
ABT450r-ABT267-ABT333 +/- Ribavirin
ABT450r-ABT267-ABT333 +/- Ribavirin is a Direct-acting antiviral (DAA) combination Small molecule drug developed by Ottawa Hospital Research Institute. It is currently FDA-approved for Chronic hepatitis C virus (HCV) infection, genotype 1. Also known as: ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin.
This is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease, NS5A protein, and NS5B polymerase, with optional ribavirin co-administration.
This is a fixed-dose combination of three direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease, NS5A protein, and NS5B polymerase, with optional ribavirin co-administration. Used for Chronic hepatitis C virus (HCV) infection, genotype 1, Chronic hepatitis C virus (HCV) infection, treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | ABT450r-ABT267-ABT333 +/- Ribavirin |
|---|---|
| Also known as | ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin |
| Sponsor | Ottawa Hospital Research Institute |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS3/4A protease, NS5A protein, NS5B polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
ABT450r is a boosted NS3/4A protease inhibitor, ABT267 is an NS5A inhibitor, and ABT333 is an NS5B non-nucleoside polymerase inhibitor. Together they target multiple steps of HCV replication. Ribavirin, when included, is a nucleoside analog that enhances viral suppression through additional mechanisms.
Approved indications
- Chronic hepatitis C virus (HCV) infection, genotype 1
Common side effects
- Fatigue
- Headache
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT450r-ABT267-ABT333 +/- Ribavirin CI brief — competitive landscape report
- ABT450r-ABT267-ABT333 +/- Ribavirin updates RSS · CI watch RSS
- Ottawa Hospital Research Institute portfolio CI
Frequently asked questions about ABT450r-ABT267-ABT333 +/- Ribavirin
What is ABT450r-ABT267-ABT333 +/- Ribavirin?
How does ABT450r-ABT267-ABT333 +/- Ribavirin work?
What is ABT450r-ABT267-ABT333 +/- Ribavirin used for?
Who makes ABT450r-ABT267-ABT333 +/- Ribavirin?
Is ABT450r-ABT267-ABT333 +/- Ribavirin also known as anything else?
What drug class is ABT450r-ABT267-ABT333 +/- Ribavirin in?
What development phase is ABT450r-ABT267-ABT333 +/- Ribavirin in?
What are the side effects of ABT450r-ABT267-ABT333 +/- Ribavirin?
What does ABT450r-ABT267-ABT333 +/- Ribavirin target?
Related
- Drug class: All Direct-acting antiviral (DAA) combination drugs
- Target: All drugs targeting HCV NS3/4A protease, NS5A protein, NS5B polymerase
- Manufacturer: Ottawa Hospital Research Institute — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for Chronic hepatitis C virus (HCV) infection, genotype 1
- Also known as: ombitasvir/paritaprevir/ritonavir, dasabuvir, ribavirin
- Compare: ABT450r-ABT267-ABT333 +/- Ribavirin vs similar drugs
- Pricing: ABT450r-ABT267-ABT333 +/- Ribavirin cost, discount & access